Key Takeaways
- HIMS tumbles in after-hours trading as expanding Q1 losses eclipse revenue gains.
- Growing subscriber base provides support, but profitability concerns weigh heavily on sentiment.
- Company outlook indicates continued expansion, though margin compression maintains downward pressure.
- Extended-hours selling intensifies as HIMS swings from prior-year profit to significant loss.
- GLP-1 product expansion offers growth potential while earnings challenges push stock downward.
Shares of Hims & Hers Health (HIMS) tumbled during extended trading hours despite the digital health platform delivering increased first-quarter revenue. The stock finished regular trading at $29.14, posting a 3.08% gain, before plummeting 9.75% to $26.30 following the earnings announcement. The after-hours decline reflected investor concerns over deteriorating profitability, margin compression, and a dramatic earnings reversal compared to the previous year.
Hims & Hers Health, Inc., HIMS
Top-Line Gains Cannot Mask Profitability Concerns
Hims & Hers delivered first-quarter revenue totaling $608.1 million, representing a 4% increase from $586.0 million in the comparable period last year. The uptick demonstrated persistent consumer demand for its telehealth offerings. Nevertheless, this incremental growth proved insufficient to alleviate investor worries about deteriorating bottom-line performance.
Gross profit margin contracted significantly to 65% from 73% recorded in the year-ago quarter. This compression reflected escalating operational expenses tied to the company’s broadening service offerings. The margin deterioration also raised questions about earnings sustainability despite growing revenue volumes.
The company reported a net loss of $92.1 million for the quarter. This marked a stark reversal from net income of $49.5 million achieved in the same quarter last year. Adjusted EBITDA similarly declined to $44.3 million from $91.1 million.
Customer Base Expands While Domestic Revenue Softens
Hims & Hers concluded the quarter with approximately 2.6 million subscribers on its platform. This represented a 9% year-over-year increase from 2.37 million subscribers. The expanding customer base strengthened the foundation for delivering customized healthcare solutions.
Average monthly revenue per subscriber decreased to $80 from $85 in the prior-year period. This 6% reduction indicated challenges in extracting higher value from existing customers. The decline partially negated the positive impact of adding new subscribers.
Domestic revenue contracted 8% to $529.9 million during the quarter. Conversely, international revenue surged to $78.2 million compared to just $7.3 million previously. This substantial overseas expansion provided crucial support for consolidated revenue amid weakening U.S. performance.
Forward Guidance Shows Growth Ambitions Amid Margin Challenges
Management provided second-quarter revenue guidance ranging from $680 million to $700 million. The company also projected adjusted EBITDA between $35 million and $55 million. This forecast translates to an EBITDA margin of approximately 5% to 8%.
For the complete 2026 fiscal year, Hims & Hers anticipates revenue between $2.8 billion and $3.0 billion. Full-year adjusted EBITDA is expected to fall within a range of $275 million to $350 million. These projections exclude any potential contributions from the pending Eucalyptus acquisition.
The organization continues investing in branded GLP-1 offerings and additional care verticals. Management also announced a transition from quarterly to annual shareholder communications. Despite these strategic initiatives, the sharp after-hours decline demonstrated that investors remain focused on margin weakness and earnings inconsistency as primary concerns for HIMS stock.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
